Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing
- 1 January 2006
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (2), 171-178
- https://doi.org/10.1016/j.ejca.2005.09.033
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the diseaseBlood, 2005
- In Vivo Assessment of Antiangiogenic Activity of SU6668 in an Experimental Colon Carcinoma ModelClinical Cancer Research, 2004
- SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in miceThe FASEB Journal, 2002
- Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor InhibitionJournal of Clinical Oncology, 2002
- Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839Seminars in Oncology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorptionEuropean Journal of Clinical Pharmacology, 1984
- Enhancement of methotrexate absorption by subdivision of doseCancer Chemotherapy and Pharmacology, 1979
- Decreased half life of cyclophosphamide in patients under continual treatmentEuropean Journal of Cancer (1965), 1979
- Methotrexate-induced malabsorption in children with acute lymphoblastic leukaemia.BMJ, 1977